GI Acid Pharmacology Flashcards
H2 Receptor Blockers - Examples and MOA
Cimetidine, Ranitidine, Famotidine, Nizatidine
MOA: Competitive inhibition for histamine H2 receptor on parietal cells, decreasing acid secretion stimulated by histamine
H2 Receptor Blockers - pharmacokinetics
Onset of action: 1-3 hours
Duration of action: 5+ hours
half-time: 1-3 hours
Excretion - renal and hepatic
H2 Receptor Blockers - ADRs and interactions
ADRs: Headache, diarrhea, dizzines, confusion, gynecomastia (cimetidine), myelosuppression
Interactions: Drugs metabolized by P450s - theophylline, phenytoin, warfarin, benzodiazepines, anti-depressants, beta-blockers
Issues with tolerance, rebound acid hypersecretion upon withdrawl (hypergastrinemia during use)
Proton Pump Inhibitor - Examples and MOA
Omeprazole, Lansoprazole, Esomeprazole
MOA: Given as a prodrug that is taken in by the basolateral parietal cell, incorporated into the tubulovesicular system, activated in the acid secreting vesicle, and covalently binds the H+ ATPase at a cysteine residue, rendering its conformation inactive.
More potent than H2 Blockers
Proton Pump Inhibitor - Pharmacokinetics
Distribution: 95% protein bound Metabolism: CYP2C19, CYP3A4 Excretion: omeprazole - renal > fecal, lansoprazole - fecal > renal Plasma Peak Time - 2 hrs Half-life - 1-1.5 hours
Proton Pump Inhibitor - ADRs, interactions
ADRs: immune/allergic type reactions
Interactions: Clopidogrel, digoxin, warfarin, H2 receptor blockers
Issues with tolerance, rebound acid hypersecretion upon withdrawl (hypergastrinemia during use)
Consequences of Achlorhydria
1) Hypergastrinemia -> trophic effect on CCKa receptor, causing ECL cell hyperplasia
2) B12 malabsorption -> folate deficiency (anemia), homocysteinemia (hypercoagulability)
3) Divalent Cation Malabsorption - Ca, Mg, Fe, Zn (require acid solubilization)
4) GI overgrowth of H. pylori, C. difficle, Candida, etc (NO, lysozyme, acid are protective)
5) Effects 1,2, 4 cause inflammation of gastric mucosa –> gastric polyps
6) Metabolic bone disease (homocysteinemia + secondary hyperparathyroidism)